Boston Scientific has raised its 2025 profit outlook to between $2.95 and $2.99 per share amid strong Q2 performance in its cardiovascular unit, driven in large part by the uptake of its Farapulse pulsed field ablation (PFA) system.
The company now anticipates an adjusted profit of $2.95 to $2.99 per share for 2025, raising its previous guidance of $2.87 to $2.94.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Boston Scientific鈥檚 financials revealed total sales of more than $5bn in Q2 2025, representing a 22.8% rise on Q2 2024 at $4.12bn, with shares in the company rising by over 4% following the result鈥檚 announcement.
The majority of the quarter鈥檚 profits emanated from the US-based company鈥檚 cardiovascular unit at $3.34bn 鈥� representing a 26.8% increase on the unit鈥檚 Q2 2024 performance at $2.63bn.
GlobalData medical analyst David Beauchamp noted that since its emergence, PFA has displaced most other approaches to treating atrial fibrillation (AFib) such as radiofrequency (RF) and cryoablation. Meanwhile, Boston Scientific only has competition in the space from Medtronic and Johnson & Johnson (J&J).
Boston Scientific gained US Food and Drug Administration (FDA) approval on Farapulse in January 2024, a month after Medtronic鈥檚 approval for its PulseSelect PFA system. J&J secured approval for its Varipulse PFA system in November 2024.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBeauchamp said: 鈥淏oston Scientific also has had widespread success with their WATCHMAN series of left atrial appendage closure devices.
鈥淚t’s not shocking to see them increasing their profit expectations, as they have been consistently successful for years and their device quality is very high.鈥�
Elsewhere across the business, Boston Scientific reported a 26.9% rise to $676m in its urology unit, up from $525m in Q2 2024. The company鈥檚 peripheral intervention division also saw a significant increase of 18.3% to $698m versus $590m in Q2 2024.
Boston Scientific’s chairman and CEO Mike Mahoney commented: 鈥淭his was another excellent quarter 鈥� marked by exceptional top-line performance 鈥� that delivered margin expansion and prioritised investment for future growth.鈥�
Reflecting on the quarter during an earnings call with analysts, the company’s CFO John Monson said that sales for medical device makers such as Boston Scientific had been boosted due to a growth in surgical procedures, thereby helping ameliorate broader concerns about healthcare spending concerning the Trump administration鈥檚 proposed tariffs.
However, Monson commented: “Based on the current schedule of expected tariffs, we now anticipate a full-year headwind of about $100m, down from a $200m estimate.鈥�
According to GlobalData analysis, months after the approval of Farapulse and Medtronic鈥檚 PulseSelect, physicians in the US had already started displaying a much stronger preference for Farapulse over PulseSelect.
J&J also released its , reporting a 7.3% rise in its Medtech unit on Q2 2024 to around $8.54m. Since its FDA approval in 2024, J&J鈥檚 Varipulse PFA system has clearly had an effect on the Medtech unit鈥檚 performance, albeit to a lesser extent than Farapulse given that Boston Scientific鈥檚 PFA system has had a slight head start in the market.
